The anti-inflammatory effect of catecholamines in the peritoneal cavity and hind paw of the mouse.
1. Carrageenin or 5-hydroxytryptamine-induced oedema of the mouse hind paw was antagonized by catecholamines acting on both alpha- and beta-adrenoceptors.2. Increased permeability of the mouse peritoneum induced by the local injection of acetic acid or pro-inflammatory mediators was antagonized by catecholamines acting predominantly on beta-adrenoceptors.3. The anti-inflammatory effect of catecholamines was due neither to hyperglycaemia nor to the release of adrenal cortical hormones.
D000315:Adrenalectomy; D000605:Amino Alcohols / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001786:Blood Glucose; D001920:Bradykinin / Q000627:therapeutic use; D002199:Capillary Permeability / Q000187:drug effects; D002395:Catecholamines / Q000627:therapeutic use*; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D004487:Edema / Q000188:drug therapy; D004837:Epinephrine / Q000627:therapeutic use; D006614:Hindlimb; D006632:Histamine / Q000627:therapeutic use; D006854:Hydrocortisone / Q000627:therapeutic use; D007328:Insulin / Q000494:pharmacology; D007545:Isoproterenol / Q000627:therapeutic use; D051379:Mice; D009578:Nitrobenzenes / Q000627:therapeutic use; D009638:Norepinephrine / Q000627:therapeutic use; D010529:Peritoneal Cavity; D010643:Phenoxybenzamine / Q000627:therapeutic use; D011433:Propranolol / Q000627:therapeutic use; D013015:Sotalol / Q000627:therapeutic use; D013565:Sympatholytics / Q000627:therapeutic use
D000605:Amino Alcohols; D000893:Anti-Inflammatory Agents; D001786:Blood Glucose; D002395:Catecholamines; D007328:Insulin; D009578:Nitrobenzenes; D013565:Sympatholytics; D010643:Phenoxybenzamine; D004295:Dihydroxyphenylalanine; D006632:Histamine; D011433:Propranolol; D013015:Sotalol; D007545:Isoproterenol; D001920:Bradykinin; D004298:Dopamine; D006854:Hydrocortisone; D009638:Norepinephrine; D004837:Epinephrine